We sought to determine whether the therapeutic effect of low-dose IL-2 in DSS-induced colitis is associated with phosphoinositide 3-kinase (PI3K)-protein kinase B (AKT) downregulation, given that the PI3K-AKT pathway was significantly enriched in Cluster 4—the largest cluster—which was upregulated in the DSS+PBS group and downregulated by treatment with low-dose IL-2 (16K IU/day). The gene discussed is IL2; the disease is colitis.